making a list and checking it twice... By the e

making a list and checking it twice...

By the end of 2014 the Company anticipates:

Announcing data from our ongoing LP-002 clinical study

Completing the validation work at Icon to support LymPro’s launch

Submission of the package to CLIA to support commercial launch as an LDT

Announcing data for MANF in an undisclosed orphan indication at Targeting Ocular Disorders on October 6th, 2014 in Boston

Filing an orphan drug designation application with the FDA for MANF in Retinitis Pigmentosa and immediately thereafter will be submitting a second ocular orphan drug application for MANF with the FDA

Initiating GMP manufacturing for MANF to support first-in-man clinical trials

Additional data from ongoing MANF ocular studies

Data from studies with Renishaw related to MANF’s Convection Enhanced Delivery use for Parkinson’s disease

Submit request for Pre-IND meeting with the FDA for Eltoprazine next week

Receive Feedback from the FDA on our proposed PD LID trial design (of note, based on a further analysis of the data we expect the trial to be significantly less than 200 patients) and finalize the trial design

Submit the IND to the FDA for Eltporazine

Potentially have the first patient in potential Eltporazine trial for PD LID (due to the holidays this could end up being very early in 2015) in or around the JP Morgan Healthcare Conference -

See more at: http://www.thechairmansblog.com/amarantus-bio...iLepO.dpuf